Phân tầng nguy cơ trong bệnh cơ tim phì đại

Phan tang 0U t trong bent co'tim phi da 15.85, Trén Vi Minh Thy Bệnh tiện da koTaam Anh HOV NGH SIU AM TOAN QUOC LAN TH sku VSUM / THEA NATO CONGRESS OF VETNANESE SOCEY OF WUTRASOLND N HEDINE Tinh phd Hub gy O10 thi09nnm 4] Hun Cy, March 009, a4 ""I HM Mo dau Tansuat 1500 i/ + Phi dai don dc co'tim, chi yeu lady tht tr, : a "Khong [a hau qua cua cdc bénh lệ thống, lận tin lay lệnh chuydaenae + Be dy vach tim cudi tm rac > 15 mm bat ci vit ndo cla tht ta + Be dy ti 13-14 mm trén ng cd mang gene BCTPD hose nguci cd bénh st gia din co BCTPD / tlna Abela etl (203), European Heart Jornal, 0, 1-124 a4 i \ Jin lên tỊ hiên $y lên lim ER cud Lénh tinh On inh (Tuitho Binh Spinto etal N Engl Med, 10733971245 thudng) Lên quan gif bénh co tim ph dal va dott Hii (340) th in thudug 04) bea ken ion (34) Vi dong mach ci (24) sarcoidosis (1%) bea co tim din nd (24) hep ding nyc ch) MaroBnl, Doerr JJ, Maas TS etl 2006)‘S,udden deahs in young competitive ahees (/ Roiloan ni Kich boat may phé rung cy doc Nhio nhanh thatva rung that MpHzMM Apart varung th / Rung tha Maron Bd, Shen IK, Link MS et l(200), fica of implantable cardioverter defitiators forthe \ÑM/ prevention of sudden deat inpatients wth hypertrophic cardomyopaty’ | Enf la, 30, 383313 h \y Ss=Hieu qua cla ICD trong phiong nga dott Phong ngira thu phat Ty lé tich I Gy sSc Gién £ ian đầu (%6) = S=s = = S s 2 = Phòng ngừa tiên phat Ss~ = 0 2 4 6 8 10 1 14 (CD: may ph ung cay dune Nắm đặt mát phá rung tất được \SUM / Maron BJ, Shen WK, Link MS etl (200), “Eficacy ofimplantable crave deflator forthe adi: ( preventionof sudden death inpatients with hypertrophic cardomyopathy”’ Engl Med, $42, $06 2023 ESC Cardiomyopathy Guidelines High Moderate MTC TONG ' Tầnngafth nuuờifttử "Ti "Nt aE ED CTA OMA sco CNN Dy TAU a Don Л:01/1)0)2711010)000)110)00) OTN GershB etal (2011),‘ACCH/AHA Guideline forthe Diagnoss and Treatmentof Hypertrophic Cardiomyopathy: a report ofthe American College of Cardiology Foundation/Amercan Heart Association Task Frce on Practice Guidelines’, Circultion, 124:2761-2796, Ello PM etl (2044), "2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy The Task Foe a he Dag Magen pt Cardiomyopathy ofthe European Society of Cardiology \Ñ (ESC)’ European fturl luimil (ti) flauhtaflhÚM Twong quan gia sing ob va yeu tO nguy co Gt tong BCTPE 100 Khong c6 yentguy co 4 © mnt yeu tO ny co baytOengnuy co hai yeyueuttoo nguy co : n-4 ị wo 30+ 40+ Log rank for trend p = 0.0922 bon yeu tO nguy co a 3 4 5 67 T7 0 12 Theo di xin) 8 90 Eliot PM etal Left ventricular outfltorawct obstruction and sudden deat isk inpatienwtsh Chi din dat CD theo AHA Tien cannguntgin! Nen dat CD ANNUaN (lữ TCIMTNL oh | Cothé yem xb dat CD SOMERS Fee MUG CG Ihiphanh ti thôn kế tài > Yom yet yeu tb nguy oo kde Pee d — | kon J hi Co the xem xt 10D AIRE) | CD hg che hn Getsh Bet al, 2011 “ACCF/AHA Guideline forthe Diagnoss and Treatment of Hypertrophic